Close Menu

Breaking News

The partners will research the ability of Biocept's Target Selector molecular assay to determine EGFR status in non-small cell lung cancer patients.

The company will issue units representing an aggregate of shares of common stock and warrants to purchase stock shares at an aggregate purchase price of $5.72.

The Chinese company will use the funds to accelerate the registration and commercialization of its NGS-based products for cancer screening and early detection.

The company, which had received a request from the FDA for more information on the test, is planning additional studies before resubmitting the application.

PreludeDx's DCISionRT test is for women diagnosed with ductal carcinoma in situ or stage 0 breast cancer who are treated with breast-conserving surgery.

The researchers found new molecular pathways of resistance, including hypoxia tolerance, protein folding, and mitochondria respiration.

With the help of ancient and modern DNA samples, the researchers found some overlap between the spread of genetic ancestry and languages in East Asia.

The agency cautioned test companies that the presence of mutations in the virus could lead to false negative results.

The companies will work together to develop new next-generation sequencing-based panels for research and diagnostics of inherited diseases.

Last week, GenomeWeb's readers were most interested in the Biden administration's plan to provide $1.6 billion for COVID-19 testing and genomic sequencing.

The test, developed at George Mason, measures HER2 activation in a breast cancer biopsy to help determine if a patient will respond to treatment.

Starting with a genome-wide association study focused on skin pigmentation, investigators identified genetic variants with additional ties to vitamin D levels.

Researchers reclassified 86 percent of variants initially determined to be VUS, potentially changing surveillance or treatment approaches for patients.

News items for the week of Feb. 15, 2021.

Initial partners in the program include Thermo Fisher Scientific, GNS Healthcare, DNAnexus, Personal Genome Diagnostics, and the Wellcome Sanger Institute.

A federal court ruled this week that IonPath's MIBIscope does not infringe on Fluidigm's technology, though the company has indicated it will likely appeal.

TruGenX claims that Thermo Fisher's technical support did not resolve testing issues for months, damaging its business and reputation.

The companies have worked together on a number of other cancer-related projects, including a companion diagnostic for the ovarian cancer treatment olaparib.

The firm said it intends to apply to obtain FDA Emergency Use Authorization and 510(k) clearance for a panel that detects respiratory targets in a single test.

The company's service revenues increased 157 percent to $457.9 million due to significant COVID-19 testing volumes, slightly offset by lower base business volumes.

The firm's rapid immunoassay revenues jumped ninefold due to more than $587 million in sales of SARS-CoV-2 viral antigen tests.

The institute offers a rapid whole-genome sequencing test designed to diagnose infants and children suspected of having a rare genetic condition.

The mutations in these underappreciated noncanonical genes were overrepresented in the E. coli genomes, indicating they were clinically relevant.

Pages

Nature News writes that additional details about the UK plan for an agency to support high-risk, high-reward science are needed.

The New York Times reports that the US Food and Drug Administration has authorized Johnson & Johnson's SARS-CoV-2 vaccine.

The Wall Street Journal writes new studies are giving glimpses into the origins of SARS-CoV-2.

In PLOS this week: analysis of Plasmodium population structure, qPCR assay to diagnose scabies, and more.